TC
PDSB icon

TFS Capital’s PDS Biotechnology PDSB Stock Holding History

TFS Capital’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,004
Closed -$206K – 267
2017
Q2 		$206K Sell
1,004
-146
-13% -$28.8K 0.08% 440
2017
Q1 		$209K Buy
+1,150
New +$228K 0.07% 476
2016
Q2 		– Sell
-664
Closed -$121K – 1132
2016
Q1 		$121K Buy
+664
New +$119K 0.02% 862

Other funds holding PDSB

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

TFS Capital's PDSB Position: Q3 2017 in Review

TFS Capital sold out of PDS Biotechnology (PDSB) in Q3 2017, closing a stake of 1,004 shares — an estimated $206K sold.

TFS Capital first reported a position in PDSB in Q1 2016 and held it in 3 quarters. The position peaked at $209K in Q1 2017. 55 funds tracked by Wall St. Rank hold PDSB as of Q3 2017.

  • TFS Capital reported no remaining PDS Biotechnology position as of Q3 2017 after selling out during the quarter.
  • TFS Capital sold 1,004 PDS Biotechnology shares in Q3 2017, an estimated $206K.
  • TFS Capital first reported a position in PDS Biotechnology in Q1 2016 and held it in 3 quarters.
  • TFS Capital's PDS Biotechnology position peaked at $209K in Q1 2017.
  • 55 funds tracked by Wall St. Rank held PDS Biotechnology as of Q3 2017.

Based on TFS Capital's 13F filing for Q3 2017.